Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients

[1]  N. Alonso,et al.  A prospective study of T‐ and B‐lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4+CD25+CD127low/−FoxP3+ T cells in patients with chronic HCV infection during pegylated interferon‐alpha2a plus ribavirin treatment , 2011, Journal of viral hepatitis.

[2]  Y. Imai,et al.  Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. , 2011, Journal of hepatology.

[3]  Angelique Zeringue,et al.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. , 2011, Gastroenterology.

[4]  H. El‐Serag,et al.  The changing pattern of epidemiology in hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  K. Nakao,et al.  Relationship between Regulatory T Cells and the Combination of Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis Type C , 2010, Intervirology.

[6]  N. Hayashi,et al.  Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis , 2009, Journal of viral hepatitis.

[7]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[8]  I. Jacobson.  Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  Y. Imai,et al.  Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin , 2009, Journal of viral hepatitis.

[10]  Y. Imai,et al.  Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin , 2009, Journal of viral hepatitis.

[11]  Barbara Rehermann,et al.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. , 2009, The Journal of clinical investigation.

[12]  S. Zeuzem,et al.  Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. , 2009, Clinical immunology.

[13]  E. Schiff,et al.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. , 2009, Gastroenterology.

[14]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[15]  G. Labbadia,et al.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. , 2009, The Journal of clinical investigation.

[16]  C. Wilson,et al.  Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes , 2009, Gut.

[17]  N. Terrault,et al.  Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. , 2008, Journal of hepatology.

[18]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[19]  Edward J Oakeley,et al.  Interferon signaling and treatment outcome in chronic hepatitis C , 2008, Proceedings of the National Academy of Sciences.

[20]  G. Gerken,et al.  Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. , 2008, The Journal of general virology.

[21]  N. Hayashi,et al.  Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon‐α and ribavirin therapy for chronic hepatitis C patients , 2007, Journal of medical virology.

[22]  Yoshiyuki Suzuki,et al.  Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.

[23]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[24]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[25]  N. Hayashi,et al.  Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. , 2006, Internal medicine.

[26]  N. Hayashi,et al.  Antiviral therapy for chronic hepatitis C: past, present, and future , 2005, Journal of Gastroenterology.

[27]  D. Dhumeaux,et al.  Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. , 2005, Journal of hepatology.

[28]  T. Poynard.  Treatment of Hepatitis C Virus: The First Decade , 2004, Seminars in liver disease.

[29]  K. Sugimoto,et al.  Suppression of HCV‐specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection , 2003, Hepatology.

[30]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[31]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[32]  S. Kamal,et al.  Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. , 2002, Gastroenterology.

[33]  S. Ikehara,et al.  Differential Regulation of Human Blood Dendritic Cell Subsets by IFNs1 , 2001, The Journal of Immunology.

[34]  J. Pawlotsky,et al.  Standardization of Hepatitis C Virus RNA Quantification , 2000, Hepatology.

[35]  N. Hayashi,et al.  Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. , 1999, Journal of immunology.

[36]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.